Literature DB >> 17182885

Oxidized low-density lipoproteins activate CD4+ T cell apoptosis in patients with end-stage renal disease through Fas engagement.

Pascal Meier1, François Spertini, Edouard Blanc, Michel Burnier.   

Abstract

Oxidized LDL (oxLDL) are cytotoxic to vascular cells, but their possible toxic action on T cells from patients with ESRD has not been evaluated. oxLDL concentrations were measured and compared in patients who were on long-term hemodialysis (HD), in patients who had ESRD and were on continuous ambulatory peritoneal dialysis, in nondialyzed patients with chronic kidney disease, and in age- and gender-matched control subjects. In parallel, the proliferative capacity of CD69+/CD4+ T cells and their rate of apoptosis, IL-2 expression, and intracellular expression of Bcl-2 and Bax were determined in vitro. The oxLDL concentrations were significantly higher in HD patients (all P = 0.001). Upon phytohemagglutinin stimulation, CD69+/CD4+ T cells from HD patients proliferated significantly less than those from the other patients' group (both P < 0.001). oxLDL but not the native LDL were led to CD69+/CD4+ T cells' program cell death in a dosage- and time-dependent manner through Fas pathway (P = 0.001). Cell surface Fas expression was followed by DNA fragmentation when CD69+/CD4+ T cells from HD patients or control subjects were cultured with oxLDL (200 microg/ml; 31 +/- 3 versus 25 +/- 3%; P = 0.001). In the presence of oxLDL, CD69+/CD4+ T cells from HD patients expressed significantly lower IL-2 levels, which strongly correlated with a decrease in the antiapoptotic Bcl-2 and conversely with an increase in the proapoptotic Bax expression. In conclusion, these data suggest that, in HD patients, exposure of activated CD4+ T cells to oxLDL leads to Fas-mediated apoptosis in association with inhibition of IL-2 expression. Subsequently, this may favor activation of mitochondria-dependent apoptotic pathways, leading to activated CD4+ T cell dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182885     DOI: 10.1681/ASN.2006050514

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  6 in total

1.  Impaired thymic export and increased apoptosis account for regulatory T cell defects in patients with non-ST segment elevation acute coronary syndrome.

Authors:  Wen-cai Zhang; Jun Wang; Yan-wen Shu; Ting-ting Tang; Zheng-feng Zhu; Ni Xia; Shao-fang Nie; Juan Liu; Su-feng Zhou; Jing-jing Li; Hong Xiao; Jing Yuan; Meng-yang Liao; Long-xian Cheng; Yu-hua Liao; Xiang Cheng
Journal:  J Biol Chem       Date:  2012-08-07       Impact factor: 5.157

2.  Evidence for anti-inflammatory effects of exercise in CKD.

Authors:  João L Viana; George C Kosmadakis; Emma L Watson; Alan Bevington; John Feehally; Nicolette C Bishop; Alice C Smith
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

3.  Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons.

Authors:  Andy Choi; Rebecca Scherzer; Peter Bacchetti; Phyllis C Tien; Michael S Saag; Cynthia L Gibert; Lynda A Szczech; Carl Grunfeld; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2010-08-14       Impact factor: 8.860

4.  Oxidative stress accelerates the carotid atherosclerosis process in patients with chronic kidney disease.

Authors:  Leila Azouaou Toualbi; Mounir Adnane; Khelfi Abderrezak; Wafa Ballouti; Medina Arab; Chahine Toualbi; Henni Chader; Ryne Tahae; Atmane Seba
Journal:  Arch Med Sci Atheroscler Dis       Date:  2020-09-14

5.  Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD.

Authors:  Pascal Meier; Dela Golshayan; Edouard Blanc; Manuel Pascual; Michel Burnier
Journal:  J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 10.121

6.  Heat shock proteins in children and young adults on chronic hemodialysis.

Authors:  Kinga Musiał; Krystyna Szprynger; Maria Szczepańska; Danuta Zwolińska
Journal:  Pediatr Nephrol       Date:  2009-05-28       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.